Semaglutide: Regulatory Status and Clinical Research Context in Australia

Also known as: Ozempic, Wegovy

What is Semaglutide?

Semaglutide is a GLP-1 receptor agonist that is the subject of international clinical research. In Australia, semaglutide is listed on the Australian Register of Therapeutic Goods (ARTG) for specific indications and is available by prescription through approved clinical pathways. It is distinct from investigational peptide compounds that may not yet have TGA approval. This page provides general information about semaglutide's regulatory and research context in Australia and is not medical advice.

Regulatory Status in Australia

Semaglutide is listed on the ARTG for specific indications in Australia. For weight management, Ozempic was approved by the TGA in 2021 for use in type 2 diabetes, and Wegovy (semaglutide specifically for weight management) received TGA approval in 2022 and was launched in Australia in 2023. Prescribing decisions are made by AHPRA-registered medical practitioners after an individual clinical assessment. Compounded versions of semaglutide may be available through compounding pharmacies under prescribing frameworks. Australians cannot legally access semaglutide without a valid prescription from a registered medical practitioner.

Research Context

Semaglutide has been studied extensively in international clinical trials including the STEP (Semaglutide Treatment Effect in People with obesity) programme. Published peer-reviewed research has investigated its effects in the context of weight management and metabolic health. These studies have been conducted in accordance with international clinical trial standards. Results have contributed to the evidence base considered by regulatory bodies including the TGA and FDA. As with all prescribed medicines, individual responses vary and ongoing monitoring by a treating practitioner is required.

What This Means for Australians

Semaglutide is available in Australia by prescription through approved TGA pathways
An AHPRA-registered medical practitioner must assess suitability before any prescription
Consultations typically involve a thorough medical history and discussion of treatment goals
Telehealth consultations are available with many clinics for patients across Australia
Use Peptide Finder to compare clinics offering weight management consultations

This page provides general information only and is not medical advice. Always speak with a qualified healthcare professional before starting any new medical treatment. Any prescribing decision is made by the treating practitioner after an individual clinical assessment.

Compare Clinics

26 clinics offering related consultations. Compare details, then contact the clinic that looks like the best fit.

Peptide Finder is a clinic directory only. We do not prescribe, supply, or advertise prescription medicines. Suitability is determined by the prescribing doctor at consultation.

Elite

GL Vitality Drips

Sydney, NSW

4.9(32)

Director-led, Australia-wide telehealth service connecting clients with AHPRA-registered doctors and licensed compounding pharmacies. Medical oversight is provided by Dr. Harrison Weisinger (Dr. Harry), an Australian family doctor with a PhD in preventative and evidence-based healthcare. Founded by Gemma - clients liaise directly with her throughout their program.

Injury RecoveryWeight ManagementMuscle & PerformancePlus more

Aus-wide delivery